1-2 of 2
Jamie Cavenagh
Close
Sort by
Journal Articles

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Clinical Trials & Observations
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, Steve Knapper, Sylvie D. Freeman, Leona M. Batten, Joanna Canham, Emily L. Hinson, Julie Wych, Sophie Betteridge, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4539–4549.
https://doi.org/10.1182/bloodadvances.2023010276
Published: 2023
Includes: Supplemental data
Journal Articles

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

Clinical Trials & Observations
Marina Y. Konopleva, Christoph Röllig, Jamie Cavenagh, Dries Deeren, Larisa Girshova, Jürgen Krauter, Giovanni Martinelli, Pau Montesinos, Jonas A. Schäfer, Oliver Ottmann, Mario Petrini, Arnaud Pigneux, Alessandro Rambaldi, Christian Recher, Rebeca Rodriguez-Veiga, David Taussig, Norbert Vey, Sung-Soo Yoon, Marion Ott, Susanne Muehlbauer, Benjamin M. Beckermann, Olivier Catalani, Magali Genevray, Kirsten Mundt, Candice Jamois, Pierre Fenaux, Andrew H. Wei
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4147–4156.
https://doi.org/10.1182/bloodadvances.2021006303
Published: 2022
Includes: Supplemental data